Upstream Bio, Inc. (UPB) SEC Filings & Earnings Calls

Clinical-stage company with no approved products; Phase 3 trials may fail to meet endpoints, regulatory approval is uncertain, and commercialization is years away (2030 at earliest).

“With supportive Phase 3 results, the Company expects to submit a Biologics License Application (BLA) to the FDA for both indications, which could enable potential launch as early as 2030.” · word for word

Competition from existing TSLP-targeting therapies (e.g., Tezspire) and other pipeline candidates could limit market opportunity.

“Verekitug is the only known antagonist currently in clinical development that targets and inhibits the TSLP receptor.” · word for word

Clinical-stage company with no approved products; relies on successful trial outcomes and regulatory approvals.

“clinical-stage company developing treatments for severe inflammatory respiratory diseases” · word for word

Clinical-stage company with no approved product; high cash burn; need for additional financing

“We have incurred significant net operating losses and negative cash flows since our inception. ... We will need additional financing to support its continuing operations and pursue its growth strategy.” · word for word

Dependence on single product candidate verekitug

“Verekitug is our only product candidate, and we are dependent on a third party having accurately generated, collected and reported data from certain preclinical studies that were previously conducted for verekitug.” · word for word

Clinical trial failure risk

“If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize verekitug or any other potential future product candidates.” · word for word

Regulatory approval uncertainty

“The regulatory approval processes of the FDA, the European Medicines Agency, and the European Commission and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for verekitug or any other potential future product candidates, our business will b” · word for word

Competitive pressure

“Competitive products may reduce or eliminate the commercial opportunity for verekitug or any other potential future product candidates, if approved.” · word for word

Clinical-stage development risk

“We are a clinical-stage biopharmaceutical company with a limited operating history... we have incurred significant financial losses since our inception.” · word for word

Funding dependency

“We will require additional funding in order to finance operations.” · word for word

Clinical-stage company with no approved products; significant R&D expenses and net losses.

“Net loss $40.6M; R&D expenses $36.6M.”

Clinical trial risks; Phase 3 data expected in 2027.

“Phase 3 initiations expected Q1 2027; COPD data H2 2027.”

Pre-revenue clinical-stage biotech; no product revenue or commercial operations described.

“No product revenue or commercial operations described in the filing.”

Pre-revenue biotech with increasing cash burn

“Net loss $ (143,443 ) $ (62,806 ) $ (80,637 )” · word for word

Dependence on single product candidate verekitug

“We have not yet commercialized verekitug and we do not expect to generate revenue from product sales of verekitug for the next several years, if at all.” · word for word

Clinical-stage company with no approved products; reliance on verekitug success.

“clinical-stage company developing treatments for inflammatory diseases” · word for word

Dilution risk from potential ATM share sales up to $150M.

“the Company may offer and sell ATM Shares having an aggregate sales price of up to $150,000,000” · word for word

Preliminary data subject to change; no audited financials.

“The Company has not yet completed its quarter-end and year-end financial close process” · word for word

Phase 3 trials still required; regulatory approval not guaranteed.

“Planning activities for Phase 3 trials in severe asthma and CRSwNP have commenced” · word for word

No revenue, increasing net loss, clinical-stage risk with no approved products

Cash runway risk

“The Company expects its cash, cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the date of issuance of these condensed consolidated financial statements. The Company will need additional financing to support its continuing operations and” · word for word

Clinical-stage development risk

“We are a clinical-stage biopharmaceutical company with a limited operating history... We have incurred significant financial losses since our inception and anticipate that we will continue to incur significant financial losses for the foreseeable future.” · word for word

Single product dependency

“Verekitug is our only product candidate, and we are dependent on a third party having accurately generated, collected and reported data from certain preclinical studies that were previously conducted for verekitug.” · word for word